Eledon Pharmaceuticals, Inc. (ELDN) Stock Analysis — Probabli.AI
AI-powered analysis for ELDN (Eledon Pharmaceuticals, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $3.46 · Market cap: $239.3M · AI outlook: Bullish
Eledon Pharmaceuticals appears positioned for substantial upside. Leveraging positive clinical trials, strategic funding achievements, and orphan drug upstream development provide a strong narrative for the company's potential growth. The stock is speculative but intriguing due to upside tail-risk opportunities.
Probabilistic 1-Year Outlook
- Bull 60% · Neutral 30% · Bear 10%
- 1-year price estimates — P10: $3 / P50: $8 / P90: $12
- Eledon Pharmaceuticals has recently demonstrated positive trial results (such as for ELDN-001) and secured significant funding. Furthermore, it holds a strong analyst consensus with high implied price targets. These…
5-Year Outlook
- Bull 65% · Neutral 25% · Bear 10%
- 5-year price estimates — P10: $8 / P50: $18 / P90: $35
SWOT Highlights
- Strength: Encouraging Phase 2 results for ELDN-001
- Strength: Recent funding boosts R&D capacity
- Risk: High average EPS negative surprise
- Risk: Clinical trial and FDA approval risks
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
2 Wall Street analysts rate ELDN a STRONG BUY with a mean price target of $8.5.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
ELDN forecast details · ELDN sentiment details · ELDN insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.